<?xml version='1.0' encoding='utf-8'?>
<document id="16713428"><sentence text="N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II."><entity charOffset="44-54" id="DDI-PubMed.16713428.s1.e0" text="retigabine" /></sentence><sentence text="Retigabine (D-23129), an N-2-amino-4-(4-fluorobenzylamino)phenylcarbamine acid ethyl ester, is a novel antiepileptic drug which is currently in phase II clinical development"><entity charOffset="0-10" id="DDI-PubMed.16713428.s2.e0" text="Retigabine" /><entity charOffset="25-90" id="DDI-PubMed.16713428.s2.e1" text="N-2-amino-4-(4-fluorobenzylamino)phenylcarbamine acid ethyl ester" /><pair ddi="false" e1="DDI-PubMed.16713428.s2.e0" e2="DDI-PubMed.16713428.s2.e0" /><pair ddi="false" e1="DDI-PubMed.16713428.s2.e0" e2="DDI-PubMed.16713428.s2.e1" /></sentence><sentence text=" This drug undergoes N-glucuronidation" /><sentence text=" We aimed to identify the principal enzymes involved in the N-glucuronidation pathway of retigabine and compared our findings with those obtained from human liver (a pool of 30 donors) and kidney microsomes (a pool of 3 donors) and with results from a human absorption, distribution, metabolism, and excretion study upon administration of 200 microCi of [(14)C]-D-23129"><entity charOffset="89-99" id="DDI-PubMed.16713428.s4.e0" text="retigabine" /></sentence><sentence text=" Essentially, microsomal assays with UGT1A1 produced only one of the 2 N-glucuronides, whereas UGT1A9 is capable of forming both N-glucuronides"><entity charOffset="69-85" id="DDI-PubMed.16713428.s5.e0" text="2 N-glucuronides" /><entity charOffset="129-143" id="DDI-PubMed.16713428.s5.e1" text="N-glucuronides" /><pair ddi="false" e1="DDI-PubMed.16713428.s5.e0" e2="DDI-PubMed.16713428.s5.e0" /><pair ddi="false" e1="DDI-PubMed.16713428.s5.e0" e2="DDI-PubMed.16713428.s5.e1" /></sentence><sentence text=" The rates of metabolism for UGT1A9, human liver microsomes, and UGT1A1 were 200, 100, and 100 pmol N-glucuronide per minute per milligram of protein, respectively" /><sentence text=" At the 50 micromol/L uridine diphosphate glucoronic acid (UDPGA) concentration, UGT1A4 also catalyzed the N-glucuronidation of retigabine, the rates being approximately 5 and 6 pmol/(min"><entity charOffset="22-57" id="DDI-PubMed.16713428.s7.e0" text="uridine diphosphate glucoronic acid" /><entity charOffset="59-64" id="DDI-PubMed.16713428.s7.e1" text="UDPGA" /><entity charOffset="128-138" id="DDI-PubMed.16713428.s7.e2" text="retigabine" /><pair ddi="false" e1="DDI-PubMed.16713428.s7.e0" e2="DDI-PubMed.16713428.s7.e0" /><pair ddi="false" e1="DDI-PubMed.16713428.s7.e0" e2="DDI-PubMed.16713428.s7.e1" /><pair ddi="false" e1="DDI-PubMed.16713428.s7.e0" e2="DDI-PubMed.16713428.s7.e2" /><pair ddi="false" e1="DDI-PubMed.16713428.s7.e1" e2="DDI-PubMed.16713428.s7.e1" /><pair ddi="false" e1="DDI-PubMed.16713428.s7.e1" e2="DDI-PubMed.16713428.s7.e2" /></sentence><sentence text="mg protein)" /><sentence text=" With UGT1A9, the production of metabolites 1 and 2 proceeded at a K(m) of 38+/-25 and 45+/-15 micromol/L, whereas the K(m) for retigabine N-glucuronidation by human liver microsomal fractions was 145+/-39 micromol/L"><entity charOffset="128-138" id="DDI-PubMed.16713428.s9.e0" text="retigabine" /></sentence><sentence text=" Furthermore, a V(max) of 1" /><sentence text="2+/-0" /><sentence text="3 (nmol/[min" /><sentence text="mg protein]) was estimated for human liver microsomes (4 individual donors)" /><sentence text=" We investigated the potential for drug-drug interaction using the antiepileptic drugs valproic acid, lamotrigine, the tricyclic antidepressant imipramine, and the anesthetic propofol"><entity charOffset="87-100" id="DDI-PubMed.16713428.s14.e0" text="valproic acid" /><entity charOffset="102-113" id="DDI-PubMed.16713428.s14.e1" text="lamotrigine" /><entity charOffset="144-154" id="DDI-PubMed.16713428.s14.e2" text="imipramine" /><entity charOffset="175-183" id="DDI-PubMed.16713428.s14.e3" text="propofol" /><pair ddi="false" e1="DDI-PubMed.16713428.s14.e0" e2="DDI-PubMed.16713428.s14.e0" /><pair ddi="false" e1="DDI-PubMed.16713428.s14.e0" e2="DDI-PubMed.16713428.s14.e1" /><pair ddi="false" e1="DDI-PubMed.16713428.s14.e0" e2="DDI-PubMed.16713428.s14.e2" /><pair ddi="false" e1="DDI-PubMed.16713428.s14.e0" e2="DDI-PubMed.16713428.s14.e3" /><pair ddi="false" e1="DDI-PubMed.16713428.s14.e1" e2="DDI-PubMed.16713428.s14.e1" /><pair ddi="false" e1="DDI-PubMed.16713428.s14.e1" e2="DDI-PubMed.16713428.s14.e2" /><pair ddi="false" e1="DDI-PubMed.16713428.s14.e1" e2="DDI-PubMed.16713428.s14.e3" /><pair ddi="false" e1="DDI-PubMed.16713428.s14.e2" e2="DDI-PubMed.16713428.s14.e2" /><pair ddi="false" e1="DDI-PubMed.16713428.s14.e2" e2="DDI-PubMed.16713428.s14.e3" /></sentence><sentence text=" These are commonly used medications and are extensively glucuronidated" /><sentence text=" No potential for drug-drug interactions was found at clinically relevant concentrations (when assayed with human liver microsomes or UGT1A9 enzyme preparations)" /><sentence text=" Notably, the biosynthesis of retigabine-N-glucuronides was not inhibited in human liver microsomal assays in the presence of 330 micromol/L bilirubin, and glucuronidation of retigabine was also observed with microsomal preparations from human kidney and Crigler-Najjar type II liver"><entity charOffset="30-55" id="DDI-PubMed.16713428.s17.e0" text="retigabine-N-glucuronides" /><entity charOffset="141-150" id="DDI-PubMed.16713428.s17.e1" text="bilirubin" /><entity charOffset="175-185" id="DDI-PubMed.16713428.s17.e2" text="retigabine" /><pair ddi="false" e1="DDI-PubMed.16713428.s17.e0" e2="DDI-PubMed.16713428.s17.e0" /><pair ddi="false" e1="DDI-PubMed.16713428.s17.e0" e2="DDI-PubMed.16713428.s17.e1" /><pair ddi="false" e1="DDI-PubMed.16713428.s17.e0" e2="DDI-PubMed.16713428.s17.e2" /><pair ddi="false" e1="DDI-PubMed.16713428.s17.e1" e2="DDI-PubMed.16713428.s17.e1" /><pair ddi="false" e1="DDI-PubMed.16713428.s17.e1" e2="DDI-PubMed.16713428.s17.e2" /></sentence><sentence text=" This suggests that lack of a particular UDP-glucuronosyltransferase (UGT) isoform (eg, UGT1A1 in kidney) or functional loss of an entire UGT1A gene does not completely abolish disposal of the drug" /><sentence text=" Finally, chromatographic separations of extracts from microsomal assays and human urine of volunteers receiving a single dose of (14)C-retigabine provided clear evidence for the presence of the 2 N-glucuronides known to be produced by UGT1A9"><entity charOffset="130-146" id="DDI-PubMed.16713428.s19.e0" text="(14)C-retigabine" /><entity charOffset="195-211" id="DDI-PubMed.16713428.s19.e1" text="2 N-glucuronides" /><pair ddi="false" e1="DDI-PubMed.16713428.s19.e0" e2="DDI-PubMed.16713428.s19.e0" /><pair ddi="false" e1="DDI-PubMed.16713428.s19.e0" e2="DDI-PubMed.16713428.s19.e1" /></sentence><sentence text=" We therefore suggest N-glucuronidation of retigabine to be of importance in the metabolic clearance of this drug"><entity charOffset="43-53" id="DDI-PubMed.16713428.s20.e0" text="retigabine" /></sentence><sentence text="" /></document>